Alpha Cognition (NASDAQ:ACOG) Announces Earnings Results, Misses Estimates By $0.03 EPS

Alpha Cognition (NASDAQ:ACOG) released its quarterly earnings results on Thursday. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03), Zacks reports. Alpha Cognition had a negative return on equity of 68.21% and a negative net margin of 202.23%.The company had revenue of $2.60 million during the quarter, compared to the consensus estimate of $4.41 million.

Here are the key takeaways from Alpha Cognition’s conference call:

• Strong early commercial traction — Q4 dispensed 4,941 bottles (1,859 in December), Q4 net product revenue of $2.5M and YTD product sales of $6.8M, with prescribers up 50% vs Q3 and high repeat ordering (82% of ordering homes).
• Payer progress — executed a second national PBM contract (now contracted with 2 of the top 4 PBMs); company expects downstream plan-level pull-through beginning in Q2 with broader implementation in Q3, though payer access remains a material friction point.
• Clinical and safety momentum — management reports minimal spontaneous GI adverse events, launched three real‑world studies (BEACON, CONVERGE, RESOLVE) with toplines in Q3–Q4 2026, and plans a sublingual PK study in Q2 targeting clinic entry in early 2027.
• Financial posture reflects heavier investment — FY2025 operating loss widened; 2026 operating expenses expected at $54–58M; the company holds approximately $66M in cash (post raise) providing runway into 2027 while targeting operational profitability in 2027.
• Commercial scaling initiatives — sales force expansion is largely filled, nearly 3,856 unique homes reached to date, and 48 KOLs trained for national peer‑to‑peer education intended to accelerate adoption in long‑term care.

Alpha Cognition Price Performance

ACOG stock traded down $0.26 on Friday, reaching $5.08. 111,422 shares of the company traded hands, compared to its average volume of 42,255. The firm has a fifty day simple moving average of $5.57 and a 200-day simple moving average of $6.28. The company has a market cap of $110.44 million, a P/E ratio of -4.38 and a beta of 2.55. Alpha Cognition has a one year low of $3.75 and a one year high of $11.54.

Hedge Funds Weigh In On Alpha Cognition

Several institutional investors and hedge funds have recently modified their holdings of ACOG. Opaleye Management Inc. grew its stake in shares of Alpha Cognition by 1,698.5% in the fourth quarter. Opaleye Management Inc. now owns 2,070,784 shares of the company’s stock worth $13,460,000 after acquiring an additional 1,955,642 shares during the period. AWM Investment Company Inc. lifted its position in Alpha Cognition by 52.6% during the fourth quarter. AWM Investment Company Inc. now owns 1,672,168 shares of the company’s stock valued at $10,869,000 after purchasing an additional 576,516 shares during the period. Alyeska Investment Group L.P. bought a new position in Alpha Cognition during the fourth quarter valued at approximately $2,372,000. Cable Car Capital LP boosted its holdings in Alpha Cognition by 68.8% in the second quarter. Cable Car Capital LP now owns 869,002 shares of the company’s stock worth $8,108,000 after purchasing an additional 354,278 shares during the last quarter. Finally, Sphera Funds Management LTD. boosted its holdings in Alpha Cognition by 67.6% in the fourth quarter. Sphera Funds Management LTD. now owns 567,616 shares of the company’s stock worth $3,690,000 after purchasing an additional 228,864 shares during the last quarter.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Alpha Cognition in a report on Friday, December 19th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, Alpha Cognition presently has an average rating of “Buy” and a consensus target price of $18.00.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.